pharma · SBRT · Covid19 · GRTX
Kailera Therapeutics
Galera Therapeutics
Kailera Therapeutics is a pharma organization headquartered in Waltham, USA. It trades on NYSE under ticker GRTX. Primary therapeutic focus areas include SBRT, Covid19, Head and Neck Cancer, Oral Mucositis, Esophagitis.
Waltham, Massachusetts, United States HQ
2024 Founded
153 Employees
Public company Type
GRTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, Massachusetts, United States
- Founded
- 2024
- Employees
- 153
- Programs
- 17
- Drugs
- 7
- Patents
- 23
Drug: GC4419
Phase 2 · small molecule · Head and Neck Cancer
Drug: GC4419 for Head and Neck Cancer is a Phase 2 program (small_molecule) at Galera Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GTI-4419-202
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Galera Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Head and Neck Cancer
- Status
- completed
- Trials
- 1